The Drug Discovery Platform provides structure-based drug design and synthetic support to researchers. With our drug discovery expertise and state-of-the-art analytical instrument facilities, we identify and validate promising new biological and chemical entities (including biomarkers) for life-threatening diseases. The new therapeutic entities then undergo a series of optimization processes to deliver drug candidates (CDs) which may ultimately lead to clinical trials in the Centre for Innovative Medicine (CIM). The Drug Discovery Platform also provides access and training to users from both academia and industry on a broad range of cutting-edge technologies.
Structure-based drug design, synthesis and analytical support to discover promising new therapeutics
This fall the traditional McGill-CIHR Drug Development Training Program (DDTP) Annual Retreat expanded into the first annual International Drug Discovery and Development Forum. With the theme of "Inspiring Drug Discovery Successes," this forum marked the inaugural year of the RI-MUHC's state-of-the-art Drug Discovery Platform at the Glen site.